fetal antigens C, c, D, E, Duffy (Fya), Kell (K)
UNITY™ sgNIPT has shown > 98.5% sensitivity and >99% speciﬁcity in a peer reviewed publication.
It has also shown 100% concordance with newborn screen results in NIH-sponsored clinical study with Baylor College of Medicine and a study with University of Alabama Birmingham.
Single-Molecule Accuracy Powered by QCT™
Using QCT™ molecular counting technology, UNITY™ is able to differentiate homozygous affected fetus (colored bars) from carrier fetus (gray bar). In addition, UNITY™ performs a paternal allele assay to detect a fetus at-risk to be compound heterozygous for CFTR or HBB at >98% detection rate.
Exemplary Readout. Chromosome 21 Ratio: euploid vs trisomy 21
UNITY™ sgNIPT and Aneuploidy + RhD NIPT use synthetic molecules and computational decoding in the bioinformatics stage to reduce the assay amplification noise down to the theoretical limit. Thanks to these proprietary technologies, UNITY™ can uniquely offer reflex sgNIPT and Rh NIPT solutions.
NEW! For alloimmunized patients, UNITY now screens for the presence of RBC fetal antigens associated with severe HDFN
While rare, Hemolytic Disease of the Fetus and Newborn (HDFN) can be deadly. Screening for C, c, D, E, Duffy (Fya), and Kell (K) antigens can now be added to any UNITY aneuploidy order.